Skip to content

Molecular characteristics of lung cancer lymph node metastasis detected by NGS technology and comparison with pathological diagnosis

Molecular characteristics of lung cancer lymph node metastasis detected by NGS technology and comparison with pathological diagnosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600124990
Enrollment
Unknown
Registered
2026-05-20
Start date
2026-05-31
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

Gold Standard:Pathological diagnosis
Index test:Next-generation sequencing
genetic testing

Sponsors

First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18-70 years old; 2. According to the 8th edition of the Surgical Standards published by the People's Health Press, patients with preoperative blood pressure controlled below 160/100mmHg and blood glucose controlled between 5. 6-11.2 mmol/L, and normal function of major organs such as the heart, lungs, liver, and kidneys; 3. Patients with clinical staging of cT1-3N0-2 and multidisciplinary discussions deemed to have the opportunity for surgery; 4. Surgical radical resection of lung lesions must be performed and systematic lymph node dissection must be performed; 5. Postoperative pathological diagnosis confirmed non-small cell lung cancer, including adenocarcinoma, squamous cell carcinoma, and other types of non-small cell lung cancer; 6. All postoperative tissue samples underwent genetic testing; 7. The clinical medical records are complete.

Exclusion criteria

Exclusion criteria: 1. Patients who have undergone anti-tumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) before surgery; 2. Patients with a history of other malignant tumors in the past; 3. Patients with combined second primary cancer at the time of enrollment; 4. There is a distant metastatic lesion; 5. The missing case data makes it difficult to determine the staging; 6. Other patients who cannot receive surgical treatment.

Design outcomes

Primary

MeasureTime frame
Sensitivity;Negative predictive value;Positive predictive value;Specificity;

Countries

China

Contacts

Public ContactChen Xiaobo

First Affiliated Hospital of Kunming Medical University

chenxiaobo0416@163.com+86 871 6532 4888

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026